景峰医药(000908) - 2022 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2022 was CNY 181,402,884.35, representing a 50.08% increase compared to CNY 120,869,292.97 in the same period last year[4] - Net profit attributable to shareholders decreased by 87.88% to CNY 3,338,005.22 from CNY 27,546,229.31 year-on-year[4] - Net profit for Q1 2022 was CNY 12,166,960.10, down 36.6% from CNY 19,202,159.72 in Q1 2021[22] - The net profit attributable to the parent company was CNY 3,338,005.22, a decline of 87.9% compared to CNY 27,546,229.31 in the previous year[22] - The company reported a basic and diluted earnings per share of CNY 0.0038, down from CNY 0.0313 in the same quarter last year[23] Cash Flow - The net cash flow from operating activities dropped significantly by 97.18% to CNY 3,446,754.01, down from CNY 122,196,127.27 in the previous year[11] - Operating cash flow net amount was CNY 3,446,754.01, significantly lower than CNY 122,196,127.27 in Q1 2021[25] - The cash flow from investing activities increased by 14.09% to CNY 84,691,218.51, attributed to the disposal of equity in Jingze Bio[11] - The net cash flow from investment activities was 84,691,218.51 CNY, an increase from 74,233,389.56 CNY in the previous year[27] - The total cash inflow from financing activities was 152,867,000.00 CNY, while the cash outflow was 105,385,861.43 CNY, resulting in a net cash flow of -105,385,861.43 CNY[27] - The cash flow from the repayment of debts was 82,401,917.78 CNY, compared to 287,201,097.23 CNY in the previous year[27] Assets and Liabilities - The company's total assets decreased by 5.80% to CNY 1,688,403,554.35 compared to CNY 1,792,299,532.27 at the end of the previous year[5] - Total assets amounted to CNY 1,688,403,554.35, a decrease from CNY 1,792,299,532.27 in the previous period[20] - Current assets totaled CNY 653,190,562.90, down from CNY 677,509,437.99 at the beginning of the year, indicating a decrease of about 3.6%[17] - Non-current assets decreased from CNY 1,114,790,094.28 to CNY 1,035,212,991.45, representing a decline of approximately 7.1%[18] - Total liabilities were CNY 1,348,506,079.20, down from CNY 1,464,569,017.32, showing a reduction of about 7.9%[19] - The company's cash and cash equivalents decreased from CNY 172,176,813.40 to CNY 154,334,239.10, a decline of approximately 10.4%[17] - Accounts receivable slightly decreased from CNY 202,233,546.35 to CNY 200,082,506.86, a reduction of about 1.1%[17] - Inventory increased from CNY 155,396,312.61 to CNY 169,620,122.84, reflecting an increase of approximately 9.1%[17] - The company's short-term borrowings decreased from CNY 475,667,122.10 to CNY 422,903,579.38, a decline of about 11.1%[18] - The total equity remained stable at CNY 339,897,475.15, unchanged from the previous period[19] - The company reported a significant reduction in other payables from CNY 238,875,678.46 to CNY 205,702,671.21, a decrease of approximately 13.9%[19] Expenses - Research and development expenses were reduced by 43.90% to CNY 4,875,944.05 from CNY 8,692,269.11 year-on-year[10] - Research and development expenses decreased to CNY 4,875,944.05 from CNY 8,692,269.11, a reduction of 43.5%[20] - Sales expenses increased to CNY 85,251,973.55 from CNY 57,471,972.67, an increase of 48.4%[20] - The company reported a 101.07% increase in non-operating expenses, totaling CNY 6,898,999.53, primarily due to fixed asset disposals and inventory write-offs[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 85,930[12] - Other comprehensive income attributable to the parent company was CNY 3,337,358.11, compared to CNY 6,543,839.44 in the previous year[23]